{"protocolSection":{"identificationModule":{"nctId":"NCT01755598","orgStudyIdInfo":{"id":"115616"},"organization":{"fullName":"GlaxoSmithKline","class":"INDUSTRY"},"briefTitle":"Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults","officialTitle":"Efficacy of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342 Against TB Disease, in Adults Living in a TB Endemic Region"},"statusModule":{"statusVerifiedDate":"2019-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-08-19","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-11-16","type":"ACTUAL"},"completionDateStruct":{"date":"2018-11-16","type":"ACTUAL"},"studyFirstSubmitDate":"2012-12-19","studyFirstSubmitQcDate":"2012-12-19","studyFirstPostDateStruct":{"date":"2012-12-24","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-11-12","resultsFirstSubmitQcDate":"2019-11-12","resultsFirstPostDateStruct":{"date":"2019-12-03","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-11-12","lastUpdatePostDateStruct":{"date":"2019-12-03","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"GlaxoSmithKline","class":"INDUSTRY"},"collaborators":[{"name":"Aeras","class":"OTHER"}]},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the protective efficacy of two doses of GSK Biologicals' candidate TB vaccine against pulmonary TB, as compared to placebo. The efficacy will be evaluated in adults living in TB endemic countries and aged 18 - 50 years because pulmonary TB occurs frequently in these countries and age range. In addition, the safety and immunogenicity of the candidate tuberculosis vaccine will be evaluated in a subset of volunteers.","detailedDescription":"Case Definitions:\n\n• First case definition: A subject with clinical suspicion of pulmonary TB disease, with MTB complex identified from a sputum specimen, taken before initiation of TB treatment, by Xpert MTB/RIF and/or microbiological culture and confirmed HIV-negative at the time of TB diagnosis.\n\n• Second case definition: A subject with clinical suspicion of pulmonary TB disease, with MTB complex identified from a sputum specimen, taken before initiation of TB treatment, by Xpert MTB/RIF and confirmed HIV-negative at the time of TB diagnosis.\n\n• Third case definition: A subject with clinical suspicion of pulmonary TB disease, with MTB complex identified from a sputum specimen, taken up to four weeks after initiation of TB treatment, by Xpert MTB/RIF and/or microbiological culture and confirmed HIV-negative at the time of TB diagnosis.\n\n• Fourth case definition: A subject with clinical suspicion of pulmonary TB disease, with MTB complex identified from a sputum specimen, taken up to four weeks after initiation of TB treatment, by Xpert MTB/RIF and/or microbiological culture.\n\n• Fifth case definition: A subject for whom a clinician has diagnosed TB disease and has decided to treat the patient with TB treatment."},"conditionsModule":{"conditions":["Tuberculosis","Tuberculosis Vaccines"],"keywords":["Positive Interferon-γ release assay","Efficacy","Adults","Tuberculosis vaccine","Endemic region"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":3575,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"M72AS01 Group","type":"EXPERIMENTAL","description":"Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm.","interventionNames":["Biological: GSK Biologicals' investigational TB vaccine (GSK692342)"]},{"label":"Control group","type":"PLACEBO_COMPARATOR","description":"Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm.","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"GSK Biologicals' investigational TB vaccine (GSK692342)","description":"2 doses administered intramuscularly in the deltoid region of the arm.","armGroupLabels":["M72AS01 Group"]},{"type":"BIOLOGICAL","name":"Placebo","description":"2 doses administered intramuscularly in the deltoid region of the arm.","armGroupLabels":["Control group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incident Rates of Definite Pulmonary Tuberculosis (TB) Disease, Not Associated With HIV-infection, Meeting the Case Definition 1","description":"The incidence rate of definite pulmonary TB disease (or 100 Person-years rate) was calculated as the number of subjects reporting at least one case (n) in a group, over the sum of follow-up period expressed in years (T) in the same group, and multiplied by 100. Case definition 1 = subject with clinical suspicion of pulmonary TB disease\\*, with Mycobacterium tuberculosis (Mtb) complex identified from sputum specimen, taken before initiation of TB treatment, by Xpert MTB/RIF (Nucleic Acid Amplification Test to detect Mtb complex and resistance to rifampicin in sputum samples) and/or microbiological culture and confirmed Human Immunodeficiency Virus (HIV)-negative at the time of TB diagnosis. \\*Clinical suspicion of pulmonary TB defined as subject presenting with 1 or more of the following symptoms: unexplained cough \\> 2 weeks, unexplained fever \\> 1 week, night sweats, unintentional weight loss, pleuritic chest pains, haemoptysis, fatigue or shortness of breath on exertion.","timeFrame":"From Day 60 (i.e one month after Dose 2) up to Year 3: follow-up period for cases ends at the first occurrence of an event. For the non-cases: follow-up period ends at the date of the Month 36 visit or last contact date whichever comes first"}],"secondaryOutcomes":[{"measure":"Incident Rates of Definite Xpert MTB/Rif Positive Pulmonary TB Disease, Not Associated With HIV-infection, Meeting the Case Definition 2","description":"The incidence rate of definite Xpert MTB/Rif positive pulmonary TB disease, expressed in terms of 100 Person-years rate, was calculated as the number of subjects reporting at least one case (n) in a group over the sum of follow-up period expressed in years (T) in the same group, and multiplied by 100. Case definition 2 = a subject with clinical suspicion\\* of pulmonary TB disease, with Mtb complex identified from a sputum specimen, taken before initiation of TB treatment, by Xpert MTB/RIF and confirmed HIV-negative at the time of TB diagnosis. \\*Clinical suspicion of pulmonary TB was defined as a subject presenting with one or more of the following symptoms: unexplained cough \\> 2 weeks, unexplained fever \\> 1 week, night sweats, unintentional weight loss, pleuritic chest pains, haemoptysis, fatigue or shortness of breath on exertion.","timeFrame":"From Day 60 (i.e one month after Dose 2) up to Year 3: follow-up period for cases ends at the first occurrence of an event. For the non-cases: follow-up period ends at the date of the Month 36 visit or last contact date whichever comes first"},{"measure":"Incident Rates of Definite Pulmonary TB Disease, Not Associated With HIV-infection Meeting the Case Definition 3","description":"The incidence rate of definite pulmonary TB disease (or 100 Person-years rate) was calculated as the number of subjects reporting at least one case (n) in a group, over the sum of follow-up period expressed in years (T) in the same group, and multiplied by 100. Case definition 3 = a subject with clinical suspicion\\* of pulmonary TB disease, with Mtb complex identified from a sputum specimen, taken up to four weeks after initiation of TB treatment, by Xpert MTB/RIF and/or microbiological culture and confirmed HIV-negative at the time of TB diagnosis.\\*Clinical suspicion of pulmonary TB was defined as a subject presenting with one or more of the following symptoms: unexplained cough \\> 2 weeks, unexplained fever \\> 1 week, night sweats, unintentional weight loss, pleuritic chest pains, haemoptysis, fatigue or shortness of breath on exertion.","timeFrame":"From Day 60 (i.e one month after Dose 2) up to Year 3: follow-up period for cases ends at the first occurrence of an event. For the non-cases: follow-up period ends at the date of the Month 36 visit or last contact date whichever comes first"},{"measure":"Incident Rates of Microbiological Pulmonary TB Disease, Meeting the Case Definition 4","description":"The incidence rate of Microbiological pulmonary TB disease (or 100 Person-years rate) was calculated as the number of subjects reporting at least one case (n) in a group, over the sum of follow-up period expressed in years (T) in the same group, and multiplied by 100. Case definition 4 = a subject with clinical suspicion\\* of pulmonary TB disease, with Mtb complex identified from a sputum specimen, taken up to four weeks after initiation of TB treatment, by Xpert MTB/RIF and/or microbiological culture.\\*Clinical suspicion of pulmonary TB was defined as a subject presenting with one or more of the following symptoms: unexplained cough \\> 2 weeks, unexplained fever \\> 1 week, night sweats, unintentional weight loss, pleuritic chest pains, haemoptysis, fatigue or shortness of breath on exertion.","timeFrame":"From Day 60 (i.e one month after Dose 2) up to Year 3: follow-up period for cases ends at the first occurrence of an event. For the non-cases: follow-up period ends at the date of the Month 36 visit or last contact date whichever comes first"},{"measure":"Incidence Rates of Clinical TB Disease, Meeting the Case Definition 5","description":"The incidence rate of Clinical TB disease (or 100 Person-years rate) was calculated as the number of subjects reporting at least one case (n) in a group, over the sum of follow-up period expressed in years (T) in the same group, and multiplied by 100. Case definition 5 = a subject for whom a clinician has diagnosed TB disease and has decided to treat the patient with TB treatment.","timeFrame":"From Day 60 (i.e one month after Dose 2) up to Year 3: follow-up period for cases ends at the first occurrence of an event. For the non-cases: follow-up period ends at the date of the Month 36 visit or last contact date whichever comes first"},{"measure":"Number of Subjects With Serious Adverse Events (SAEs).","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","timeFrame":"From Day 0 up to Year 3 (during the entire study period)"},{"measure":"Number of Subjects With Any Unsolicited Adverse Events (AEs).","description":"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.","timeFrame":"During the 30-day follow-up period following vaccination, across doses (i.e. day of vaccination and 29 subsequent days after each vaccine dose)"},{"measure":"Number of Subjects With Any Solicited Local AEs in the Safety and Immune Sub-cohort","description":"Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Any redness/swelling symptom was scored as injection site redness/swelling with a diameter equal or larger than (≥) 20 millimeters (mm).","timeFrame":"During the 7-day follow-up period (i.e. day of vaccination and 6 subsequent days) after each vaccine dose"},{"measure":"Number of Subjects With Any Solicited General AEs in the Safety and Immune Sub-cohort","description":"Assessed solicited general symptoms were fatigue, fever \\[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\\], respiratory symptoms (including cough, blood in sputum, purulent sputum, shortness of breath or difficulties breathing, chest wall pain) headache, malaise and myalgia. Any = occurrence of the symptom regardless of intensity grade and relation to vaccination.","timeFrame":"During the 7-day follow-up period (i.e.: day of vaccination and 6 subsequent days) after each vaccine dose"},{"measure":"Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)","description":"Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.","timeFrame":"From Day 0 to 6 months post-dose 2 (i.e. at Month 7)"},{"measure":"Number of Subjects With Grade Equal or Greater Than 2 of Severity for Haematological and Biochemichal Abnormal Laboratory Values in the Safety and Immune Sub-cohort","description":"Abnormal laboratory values include haematological abnormalities (haemoglobin level, white blood cells and platelets) and biochemical abnormalities (alanine aminotransferase, aspartate aminotransferase and creatinine). Grading was defined based on the Food and Drug Administration \\[FDA\\], 2007. Guidance for Industry, Toxicity Grading Scale for Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Alanine Aminotransferase = ALA; Aspartate Aminotransferase = ASP; Creatinine = CREA; Hemoglobin (Change from baseline) = HEM (baseline); Hemoglobin (decrease) = HEM (decrease); Leukocytes (White Blood Cells) (Decrease) = WBC (decrease); Leukocytes (White Blood Cells) (Increase) = WBC (increase); Platelets = PLA; Total Bilirubin = BIL.","timeFrame":"Days 0, 7, 30 and 37"},{"measure":"Desciptive Statistics of the Frequency of M72-specific CD4+ T-cells Expressing Any Combination of Immune Markers in the Safety and Immune Sub-cohort","description":"The frequency of M72-specific CD4 + T-cells per million cells were identified after in vitro stimulation expressing any combination of immune markers ( Interleukin-2 (IL-2), cluster of differentiation 40-ligand (CD40-L), tumor necrosis factor alpha (TNF-) and interferon-gamma (IFN-) after background subtraction for each treatment group.","timeFrame":"Prior to dose 1 (Day 0) and post-dose 2 (Day 60, Year 1, Year 2 and Year 3)"},{"measure":"Desciptive Statistics of the Frequency of M72-specific CD8+ T-cells Expressing Any Combination of Immune Markers in the Safety and Immune Sub-cohort","description":"The frequency of M72-specific CD8 + T-cells per million cells were identified after in vitro stimulation expressing any combination of immune markers ( Interleukin-2 (IL-2), cluster of differentiation 40-ligand (CD40-L), tumor necrosis factor alpha (TNF-) and interferon-gamma (IFN-) after background subtraction for each treatment group.","timeFrame":"Prior to dose 1 (Day 0) and post-dose 2 (Day 60, Year 1, Year 2 and Year 3)"},{"measure":"M72-specific Antibody Concentrations as Measured by Enzyme Linked Immuno Sorbent Assay (ELISA) in the Safety and Immune Sub-cohort","description":"Mycobacterium tuberculosis M72-specific antibody geometric mean concentrations (GMCs) with exact 95% Confidence Interval (CI) were measured by Enzyme Linked Immuno Sorbent Assay (ELISA) and expressed in ELISA unit per milliliter (EU/mL). The cut-off of the assay was 2.8 EU/mL. The Geometric Mean Concentration (GMC) calculations were performed by taking the anti-log of the mean of the log10 concentration transformations. For descriptive statistics purposes only, antibody concentrations below the cut-off value of the assay was given an arbitrary value of half the cut-off value for the purpose of GMC calculation.","timeFrame":"Prior to dose 1 (Day 0) and post-dose 2 (Day 60, Year 1, Year 2 and Year 3)"},{"measure":"Number of Seropositive Subjects for M72 Antibodies Measured by ELISA in the Safety and Immune Sub-cohort","description":"A seronegative subject was a subject whose antibody concentration was below 2.8 EU/mL, while a seropositive subject was a subject whose antibody concentration was greater than or equal to 2.8 EU/mL.","timeFrame":"Prior to dose 1 (Day 0) and post-dose 2 (Day 60, Year 1, Year 2 and Year 3)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.\n* A male or female between, and including, 18 and 50 years of age at the time of obtaining informed consent.\n* Written (or thumb printed and witnessed) informed consent obtained from the subject.\n* Baseline positive IGRA test result.\n* Baseline negative HIV screen.\n* Baseline negative clinical screening questionnaire and negative sputum sample for Pulmonary TB disease.\n* Healthy subjects or those with chronic well-controlled disease as established by medical history and clinical examination.\n* Female subjects of non-childbearing potential may be enrolled in the study.\n\n  * Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.\n* Female subjects of childbearing potential may be enrolled in the study, if the subject:\n\n  * has practiced adequate contraception for 25 days prior to vaccination, and\n  * has a negative pregnancy test on the day of screening and the day of first vaccination, and\n  * has agreed to continue adequate contraception during the entire vaccination period and for 2 months after completion of the vaccination series.\n\nExclusion Criteria:\n\n* Current TB disease or history of TB disease and/or treatment for TB.\n* Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.\n* Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before and ending 30 days after each dose of vaccine.\n* History of previous administration of experimental Mtb vaccines.\n* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. Inhaled and topical steroids are allowed.\n* Any condition or illness or medication, which in the opinion of the Investigator might interfere with the evaluation of the safety or immunogenicity of the vaccine.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.\n* Planned participation or participation in another experimental protocol during the study.\n* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.\n* Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.\n* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.\n* History of medically confirmed autoimmune disease.\n* Pregnant or lactating female.\n* Female planning to become pregnant or planning to discontinue contraceptive precautions during the vaccination period and/or before 2 months after completion of the vaccination series.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"GSK Clinical Trials","affiliation":"GlaxoSmithKline (for GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; Sirtris, a GSK Company; Stiefel, a GSK Company; ViiV Healthcare)","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"GSK Investigational Site","city":"Kisumu","country":"Kenya","geoPoint":{"lat":-0.10221,"lon":34.76171}},{"facility":"GSK Investigational Site","city":"Pretoria","state":"Gauteng","zip":"0152","country":"South Africa","geoPoint":{"lat":-25.74486,"lon":28.18783}},{"facility":"GSK Investigational Site","city":"Soweto","state":"Gauteng","zip":"2013","country":"South Africa","geoPoint":{"lat":-26.26781,"lon":27.85849}},{"facility":"GSK Investigational Site","city":"Klerksdorp","state":"North West","zip":"2571","country":"South Africa","geoPoint":{"lat":-26.85213,"lon":26.66672}},{"facility":"GSK Investigational Site","city":"Western Cape","state":"Western Province","country":"South Africa"},{"facility":"GSK Investigational Site","city":"Worcester","state":"Western Province","zip":"6850","country":"South Africa","geoPoint":{"lat":-33.64651,"lon":19.44852}},{"facility":"GSK Investigational Site","city":"Cape Town","zip":"7530","country":"South Africa","geoPoint":{"lat":-33.92584,"lon":18.42322}},{"facility":"GSK Investigational Site","city":"Cape Town","zip":"7925","country":"South Africa","geoPoint":{"lat":-33.92584,"lon":18.42322}},{"facility":"GSK Investigational Site","city":"Lusaka","country":"Zambia","geoPoint":{"lat":-15.40669,"lon":28.28713}}]},"referencesModule":{"references":[{"pmid":"31661198","type":"DERIVED","citation":"Tait DR, Hatherill M, Van Der Meeren O, Ginsberg AM, Van Brakel E, Salaun B, Scriba TJ, Akite EJ, Ayles HM, Bollaerts A, Demoitie MA, Diacon A, Evans TG, Gillard P, Hellstrom E, Innes JC, Lempicki M, Malahleha M, Martinson N, Mesia Vela D, Muyoyeta M, Nduba V, Pascal TG, Tameris M, Thienemann F, Wilkinson RJ, Roman F. Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis. N Engl J Med. 2019 Dec 19;381(25):2429-2439. doi: 10.1056/NEJMoa1909953. Epub 2019 Oct 29."},{"pmid":"30280651","type":"DERIVED","citation":"Van Der Meeren O, Hatherill M, Nduba V, Wilkinson RJ, Muyoyeta M, Van Brakel E, Ayles HM, Henostroza G, Thienemann F, Scriba TJ, Diacon A, Blatner GL, Demoitie MA, Tameris M, Malahleha M, Innes JC, Hellstrom E, Martinson N, Singh T, Akite EJ, Khatoon Azam A, Bollaerts A, Ginsberg AM, Evans TG, Gillard P, Tait DR. Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis. N Engl J Med. 2018 Oct 25;379(17):1621-1634. doi: 10.1056/NEJMoa1803484. Epub 2018 Sep 25."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"IPD is available via the Clinical Study Data Request site (click on the link provided below)","infoTypes":["STUDY_PROTOCOL","SAP","ICF","CSR"],"timeFrame":"IPD is available via the Clinical Study Data Request site (click on the link provided below)","accessCriteria":"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.","url":"https://clinicalstudydatarequest.com/Posting.aspx?ID=20104"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Out of 3575 subjects enrolled in the study, 2 subjects did not get any vaccination and therefore were not included in any analysis.","groups":[{"id":"FG000","title":"M72AS01 Group","description":"Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."},{"id":"FG001","title":"Control Group","description":"Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"1786"},{"groupId":"FG001","numSubjects":"1787"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1521"},{"groupId":"FG001","numSubjects":"1504"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"265"},{"groupId":"FG001","numSubjects":"283"}]}],"dropWithdraws":[{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"109"},{"groupId":"FG001","numSubjects":"109"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"43"}]},{"type":"Migrated/moved from study area","reasons":[{"groupId":"FG000","numSubjects":"76"},{"groupId":"FG001","numSubjects":"65"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"31"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"28"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"M72AS01 Group","description":"Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."},{"id":"BG001","title":"Control Group","description":"Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1786"},{"groupId":"BG001","value":"1787"},{"groupId":"BG002","value":"3573"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28.9","spread":"8.3"},{"groupId":"BG001","value":"28.9","spread":"8.3"},{"groupId":"BG002","value":"28.9","spread":"8.3"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"763"},{"groupId":"BG001","value":"766"},{"groupId":"BG002","value":"1529"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"1023"},{"groupId":"BG001","value":"1021"},{"groupId":"BG002","value":"2044"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"African Heritage / African American","categories":[{"measurements":[{"groupId":"BG000","value":"1346"},{"groupId":"BG001","value":"1329"},{"groupId":"BG002","value":"2675"}]}]},{"title":"Other, Not Specified","categories":[{"measurements":[{"groupId":"BG000","value":"440"},{"groupId":"BG001","value":"458"},{"groupId":"BG002","value":"898"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Incident Rates of Definite Pulmonary Tuberculosis (TB) Disease, Not Associated With HIV-infection, Meeting the Case Definition 1","description":"The incidence rate of definite pulmonary TB disease (or 100 Person-years rate) was calculated as the number of subjects reporting at least one case (n) in a group, over the sum of follow-up period expressed in years (T) in the same group, and multiplied by 100. Case definition 1 = subject with clinical suspicion of pulmonary TB disease\\*, with Mycobacterium tuberculosis (Mtb) complex identified from sputum specimen, taken before initiation of TB treatment, by Xpert MTB/RIF (Nucleic Acid Amplification Test to detect Mtb complex and resistance to rifampicin in sputum samples) and/or microbiological culture and confirmed Human Immunodeficiency Virus (HIV)-negative at the time of TB diagnosis. \\*Clinical suspicion of pulmonary TB defined as subject presenting with 1 or more of the following symptoms: unexplained cough \\> 2 weeks, unexplained fever \\> 1 week, night sweats, unintentional weight loss, pleuritic chest pains, haemoptysis, fatigue or shortness of breath on exertion.","populationDescription":"Analysis was performed on the According-to-Protocol cohort for efficacy which included all subjects who received all vaccinations according to protocol procedures within specified intervals that contributed time at risk in the follow-up period starting one month post dose 2 (Day 60).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"90% Confidence Interval","unitOfMeasure":"cases per 100 person-years","timeFrame":"From Day 60 (i.e one month after Dose 2) up to Year 3: follow-up period for cases ends at the first occurrence of an event. For the non-cases: follow-up period ends at the date of the Month 36 visit or last contact date whichever comes first","groups":[{"id":"OG000","title":"M72AS01 Group","description":"Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."},{"id":"OG001","title":"Control Group","description":"Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1626"},{"groupId":"OG001","value":"1663"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.2","upperLimit":"0.5"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.4","upperLimit":"0.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"To evaluate the protective efficacy of two doses of the M72/AS01E candidate vaccine against Definite pulmonary TB disease not associated with HIV-infection, meeting the case definition 1, as compared to placebo.","nonInferiorityType":"OTHER","nonInferiorityComment":"Vaccine efficacy (VE) has been estimated from a Cox proportional hazard regression model (VE=1-hazard ratio) and 90% confidence intervals (CIs) and Wald p-value has been derived. The lower limit of the 90% two-sided CI for the VE against first occurrence of Definite pulmonary TB disease not associated with HIV-infection, meeting the case definition 1, is to be above 0%.","pValue":"0.0430","statisticalMethod":"Regression, Cox","paramType":"Vaccine efficacy rate","paramValue":"49.7","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"12.1","ciUpperLimit":"71.2"}]},{"type":"SECONDARY","title":"Incident Rates of Definite Xpert MTB/Rif Positive Pulmonary TB Disease, Not Associated With HIV-infection, Meeting the Case Definition 2","description":"The incidence rate of definite Xpert MTB/Rif positive pulmonary TB disease, expressed in terms of 100 Person-years rate, was calculated as the number of subjects reporting at least one case (n) in a group over the sum of follow-up period expressed in years (T) in the same group, and multiplied by 100. Case definition 2 = a subject with clinical suspicion\\* of pulmonary TB disease, with Mtb complex identified from a sputum specimen, taken before initiation of TB treatment, by Xpert MTB/RIF and confirmed HIV-negative at the time of TB diagnosis. \\*Clinical suspicion of pulmonary TB was defined as a subject presenting with one or more of the following symptoms: unexplained cough \\> 2 weeks, unexplained fever \\> 1 week, night sweats, unintentional weight loss, pleuritic chest pains, haemoptysis, fatigue or shortness of breath on exertion.","populationDescription":"Analysis was performed on the According-to-Protocol cohort for efficacy which included all subjects who received all vaccinations according to protocol procedures within specified intervals that contributed time at risk in the follow-up period starting one month post dose 2 (Day 60).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"90% Confidence Interval","unitOfMeasure":"cases per 100 person-years","timeFrame":"From Day 60 (i.e one month after Dose 2) up to Year 3: follow-up period for cases ends at the first occurrence of an event. For the non-cases: follow-up period ends at the date of the Month 36 visit or last contact date whichever comes first","groups":[{"id":"OG000","title":"M72AS01 Group","description":"Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."},{"id":"OG001","title":"Control Group","description":"Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1626"},{"groupId":"OG001","value":"1663"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.181","lowerLimit":"0.101","upperLimit":"0.323"},{"groupId":"OG001","value":"0.470","lowerLimit":"0.328","upperLimit":"0.673"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"To evaluate the protective efficacy of two doses of the M72/AS01E candidate vaccine against Definite Xpert MTB/Rif positive pulmonary TB disease not associated with HIV-infection, meeting the case definition 2, as compared to placebo.","nonInferiorityType":"OTHER","nonInferiorityComment":"Vaccine efficacy (VE) has been estimated from a Cox proportional hazard regression model (VE=1-hazard ratio) and 90% confidence intervals (CIs) and Wald p-value has been derived. If the primary objective is met, this secondary objective is to be analysed using the following success criterion: The lower limit of the 90% two-sided CI for the VE against first occurrence of Definite pulmonary TB disease not associated with HIV infection, meeting the case definition 2, is to be above 0%.","pValue":"0.0210","statisticalMethod":"Regression, Cox","paramType":"Vaccine efficacy rate","paramValue":"61.670","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"24.084","ciUpperLimit":"80.647"}]},{"type":"SECONDARY","title":"Incident Rates of Definite Pulmonary TB Disease, Not Associated With HIV-infection Meeting the Case Definition 3","description":"The incidence rate of definite pulmonary TB disease (or 100 Person-years rate) was calculated as the number of subjects reporting at least one case (n) in a group, over the sum of follow-up period expressed in years (T) in the same group, and multiplied by 100. Case definition 3 = a subject with clinical suspicion\\* of pulmonary TB disease, with Mtb complex identified from a sputum specimen, taken up to four weeks after initiation of TB treatment, by Xpert MTB/RIF and/or microbiological culture and confirmed HIV-negative at the time of TB diagnosis.\\*Clinical suspicion of pulmonary TB was defined as a subject presenting with one or more of the following symptoms: unexplained cough \\> 2 weeks, unexplained fever \\> 1 week, night sweats, unintentional weight loss, pleuritic chest pains, haemoptysis, fatigue or shortness of breath on exertion.","populationDescription":"Analysis was performed on the According-to-Protocol cohort for efficacy which included all subjects who received all vaccinations according to protocol procedures within specified intervals that contributed time at risk in the follow-up period starting one month post dose 2 (Day 60).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"90% Confidence Interval","unitOfMeasure":"cases per 100 person-years","timeFrame":"From Day 60 (i.e one month after Dose 2) up to Year 3: follow-up period for cases ends at the first occurrence of an event. For the non-cases: follow-up period ends at the date of the Month 36 visit or last contact date whichever comes first","groups":[{"id":"OG000","title":"M72AS01 Group","description":"Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."},{"id":"OG001","title":"Control Group","description":"Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1626"},{"groupId":"OG001","value":"1663"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.429","lowerLimit":"0.294","upperLimit":"0.626"},{"groupId":"OG001","value":"0.672","lowerLimit":"0.498","upperLimit":"0.908"}]}]}]},{"type":"SECONDARY","title":"Incident Rates of Microbiological Pulmonary TB Disease, Meeting the Case Definition 4","description":"The incidence rate of Microbiological pulmonary TB disease (or 100 Person-years rate) was calculated as the number of subjects reporting at least one case (n) in a group, over the sum of follow-up period expressed in years (T) in the same group, and multiplied by 100. Case definition 4 = a subject with clinical suspicion\\* of pulmonary TB disease, with Mtb complex identified from a sputum specimen, taken up to four weeks after initiation of TB treatment, by Xpert MTB/RIF and/or microbiological culture.\\*Clinical suspicion of pulmonary TB was defined as a subject presenting with one or more of the following symptoms: unexplained cough \\> 2 weeks, unexplained fever \\> 1 week, night sweats, unintentional weight loss, pleuritic chest pains, haemoptysis, fatigue or shortness of breath on exertion.","populationDescription":"Analysis was performed on the According-to-Protocol cohort for efficacy which included all subjects who received all vaccinations according to protocol procedures within specified intervals that contributed time at risk in the follow-up period starting one month post dose 2 (Day 60).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"90% Confidence Interval","unitOfMeasure":"cases per 100 person-years","timeFrame":"From Day 60 (i.e one month after Dose 2) up to Year 3: follow-up period for cases ends at the first occurrence of an event. For the non-cases: follow-up period ends at the date of the Month 36 visit or last contact date whichever comes first","groups":[{"id":"OG000","title":"M72AS01 Group","description":"Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."},{"id":"OG001","title":"Control Group","description":"Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1626"},{"groupId":"OG001","value":"1663"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.429","lowerLimit":"0.294","upperLimit":"0.626"},{"groupId":"OG001","value":"0.717","lowerLimit":"0.536","upperLimit":"0.959"}]}]}]},{"type":"SECONDARY","title":"Incidence Rates of Clinical TB Disease, Meeting the Case Definition 5","description":"The incidence rate of Clinical TB disease (or 100 Person-years rate) was calculated as the number of subjects reporting at least one case (n) in a group, over the sum of follow-up period expressed in years (T) in the same group, and multiplied by 100. Case definition 5 = a subject for whom a clinician has diagnosed TB disease and has decided to treat the patient with TB treatment.","populationDescription":"Analysis was performed on the According-to-Protocol cohort for efficacy which included all subjects who received all vaccinations according to protocol procedures within specified intervals that contributed time at risk in the follow-up period starting one month post dose 2 (Day 60).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"90% Confidence Interval","unitOfMeasure":"cases per 100 person-years","timeFrame":"From Day 60 (i.e one month after Dose 2) up to Year 3: follow-up period for cases ends at the first occurrence of an event. For the non-cases: follow-up period ends at the date of the Month 36 visit or last contact date whichever comes first","groups":[{"id":"OG000","title":"M72AS01 Group","description":"Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."},{"id":"OG001","title":"Control Group","description":"Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1626"},{"groupId":"OG001","value":"1663"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.586","lowerLimit":"0.425","upperLimit":"0.810"},{"groupId":"OG001","value":"0.850","lowerLimit":"0.651","upperLimit":"1.109"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs).","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","populationDescription":"Analysis was performed on the Total Vaccinated cohort which included all vaccinated subjects with at least one dose administered.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 0 up to Year 3 (during the entire study period)","groups":[{"id":"OG000","title":"M72AS01 Group","description":"Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."},{"id":"OG001","title":"Control Group","description":"Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1786"},{"groupId":"OG001","value":"1787"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"62"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Unsolicited Adverse Events (AEs).","description":"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.","populationDescription":"Analysis was performed on the Total Vaccinated cohort which included all vaccinated subjects with at least one dose administered.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the 30-day follow-up period following vaccination, across doses (i.e. day of vaccination and 29 subsequent days after each vaccine dose)","groups":[{"id":"OG000","title":"M72AS01 Group","description":"Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."},{"id":"OG001","title":"Control Group","description":"Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1786"},{"groupId":"OG001","value":"1787"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1207"},{"groupId":"OG001","value":"816"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Solicited Local AEs in the Safety and Immune Sub-cohort","description":"Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Any redness/swelling symptom was scored as injection site redness/swelling with a diameter equal or larger than (≥) 20 millimeters (mm).","populationDescription":"Analysis was performed on the \"safety and immunogenicity\" sub-cohort (i.e. about 150 subjects enrolled in each group and from 2 of the 3 countries \\[the third country study start was delayed as awaiting regulatory approval\\]) which included subjects with at least 1 vaccination dose documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the 7-day follow-up period (i.e. day of vaccination and 6 subsequent days) after each vaccine dose","groups":[{"id":"OG000","title":"M72AS01 Group","description":"Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."},{"id":"OG001","title":"Control Group","description":"Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"151"}]}],"classes":[{"title":"Any Pain after Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"48"}]}]},{"title":"Any Redness after Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"0"}]}]},{"title":"Any Swelling after Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"1"}]}]},{"title":"Any Pain after Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"22"}]}]},{"title":"Any Redness after Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}]},{"title":"Any Swelling after Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Solicited General AEs in the Safety and Immune Sub-cohort","description":"Assessed solicited general symptoms were fatigue, fever \\[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\\], respiratory symptoms (including cough, blood in sputum, purulent sputum, shortness of breath or difficulties breathing, chest wall pain) headache, malaise and myalgia. Any = occurrence of the symptom regardless of intensity grade and relation to vaccination.","populationDescription":"Analysis was performed on the \"safety and immunogenicity\" sub-cohort (i.e. about 150 subjects enrolled in each group and from 2 of the 3 countries \\[the third country study start was delayed as awaiting regulatory approval\\]) which included subjects with at least 1 vaccination dose documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the 7-day follow-up period (i.e.: day of vaccination and 6 subsequent days) after each vaccine dose","groups":[{"id":"OG000","title":"M72AS01 Group","description":"Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."},{"id":"OG001","title":"Control Group","description":"Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"151"}]}],"classes":[{"title":"Any Fatigue after Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"63"}]}]},{"title":"Any Headache after Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"60"}]}]},{"title":"Any Malaise after Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"29"}]}]},{"title":"Any Myalgia after Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"34"}]}]},{"title":"Any Respiratory symptoms after Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"13"}]}]},{"title":"Any Fever after Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"16"}]}]},{"title":"Any Fatigue after Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"31"}]}]},{"title":"Any Headache after Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"39"}]}]},{"title":"Any Malaise after Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"21"}]}]},{"title":"Any Myalgia after Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"21"}]}]},{"title":"Any Respiratory symptoms after Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"}]}]},{"title":"Any Fever after Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"10"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)","description":"Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.","populationDescription":"Analysis was performed on the Total Vaccinated cohort which included all vaccinated subjects with at least one dose administered.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 0 to 6 months post-dose 2 (i.e. at Month 7)","groups":[{"id":"OG000","title":"M72AS01 Group","description":"Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."},{"id":"OG001","title":"Control Group","description":"Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1786"},{"groupId":"OG001","value":"1787"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Grade Equal or Greater Than 2 of Severity for Haematological and Biochemichal Abnormal Laboratory Values in the Safety and Immune Sub-cohort","description":"Abnormal laboratory values include haematological abnormalities (haemoglobin level, white blood cells and platelets) and biochemical abnormalities (alanine aminotransferase, aspartate aminotransferase and creatinine). Grading was defined based on the Food and Drug Administration \\[FDA\\], 2007. Guidance for Industry, Toxicity Grading Scale for Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Alanine Aminotransferase = ALA; Aspartate Aminotransferase = ASP; Creatinine = CREA; Hemoglobin (Change from baseline) = HEM (baseline); Hemoglobin (decrease) = HEM (decrease); Leukocytes (White Blood Cells) (Decrease) = WBC (decrease); Leukocytes (White Blood Cells) (Increase) = WBC (increase); Platelets = PLA; Total Bilirubin = BIL.","populationDescription":"Analysis was performed on the \"safety and immunogenicity\" sub-cohort (i.e. about 150 subjects enrolled in each group and from 2 of the 3 countries \\[the third country study start was delayed as awaiting regulatory approval\\]) which included subjects with at least 1 laboratory value documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Days 0, 7, 30 and 37","groups":[{"id":"OG000","title":"M72AS01 Group","description":"Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."},{"id":"OG001","title":"Control Group","description":"Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"classes":[{"title":"Grade 2 ALA at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 ALA at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 ALA at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 ALA at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 ALA at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 ALA at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 ALA at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 ALA at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 ALA at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 ALA at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 ALA at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 ALA at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 ASP at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 ASP at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 ASP at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 ASP at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 ASP at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 ASP at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 ASP at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 ASP at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 ASP at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 ASP at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 ASP at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 ASP at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 CREA at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 CREA at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 CREA at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 CREA at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 CREA at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 CREA at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 CREA at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 CREA at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 CREA at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 CREA at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 CREA at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 CREA at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 HEM (baseline) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 HEM (baseline) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 HEM (baseline) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 HEM (baseline) at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}]}]},{"title":"Grade 3 HEM (baseline) at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 HEM (baseline) at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 HEM (baseline) at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"Grade 3 HEM (baseline) at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 HEM (baseline) at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 HEM (baseline) at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 HEM (baseline) at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 HEM (baseline) at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 HEM (decrease) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"}]}]},{"title":"Grade 3 HEM (decrease) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Grade 4 HEM (decrease) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 HEM (decrease) at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"5"}]}]},{"title":"Grade 3 HEM (decrease) at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"Grade 4 HEM (decrease) at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 HEM (decrease) at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"}]}]},{"title":"Grade 3 HEM (decrease) at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Grade 4 HEM (decrease) at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 HEM (decrease) at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}]}]},{"title":"Grade 3 HEM (decrease) at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 HEM (decrease) at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 WBC (decrease) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 WBC (decrease) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 WBC (decrease) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 WBC (decrease) at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 WBC (decrease) at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 WBC (decrease) at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 WBC (decrease) at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 WBC (decrease) at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 WBC (decrease) at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 WBC (decrease) at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 WBC (decrease) at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 WBC (decrease) at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 WBC (increase) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 WBC (increase) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 WBC (increase) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 WBC (increase) at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 WBC (increase) at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 WBC (increase) at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 WBC (increase) at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 WBC (increase) at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 WBC (increase) at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 WBC (increase) at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 3 WBC (increase) at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 WBC (increase) at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 PLA at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}]},{"title":"Grade 3 PLA at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 PLA at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 PLA at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Grade 3 PLA at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 PLA at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 PLA at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}]},{"title":"Grade 3 PLA at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}]},{"title":"Grade 4 PLA at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 PLA at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Grade 3 PLA at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 PLA at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 2 BIL at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}]}]},{"title":"Grade 3 BIL at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 BIL at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Grade 2 BIL at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Grade 3 BIL at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Grade 4 BIL at Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"146"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Grade 2 BIL at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Grade 3 BIL at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Grade 4 BIL at Day 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}]},{"title":"Grade 2 BIL at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"Grade 3 BIL at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Grade 4 BIL at Day 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Desciptive Statistics of the Frequency of M72-specific CD4+ T-cells Expressing Any Combination of Immune Markers in the Safety and Immune Sub-cohort","description":"The frequency of M72-specific CD4 + T-cells per million cells were identified after in vitro stimulation expressing any combination of immune markers ( Interleukin-2 (IL-2), cluster of differentiation 40-ligand (CD40-L), tumor necrosis factor alpha (TNF-) and interferon-gamma (IFN-) after background subtraction for each treatment group.","populationDescription":"Analysis was performed on the \"safety and immunogenicity\" sub-cohort (i.e. about 150 subjects enrolled in each group and from 2 of the 3 countries \\[the third country study start was delayed as awaiting regulatory approval\\]) which included subjects with at least 1 immune result documented.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"T cells per million cells","timeFrame":"Prior to dose 1 (Day 0) and post-dose 2 (Day 60, Year 1, Year 2 and Year 3)","groups":[{"id":"OG000","title":"M72AS01 Group","description":"Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."},{"id":"OG001","title":"Control Group","description":"Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"84"}]}],"classes":[{"title":"CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"178.0"},{"groupId":"OG001","value":"28.0","lowerLimit":"1.0","upperLimit":"135.0"}]}]},{"title":"CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"227.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"86.5"}]}]},{"title":"CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"300.5","lowerLimit":"66.5","upperLimit":"831.5"},{"groupId":"OG001","value":"53.0","lowerLimit":"1.0","upperLimit":"255.0"}]}]},{"title":"CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"480.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"113.5"}]}]},{"title":"CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"670.5","lowerLimit":"319.0","upperLimit":"1320.0"},{"groupId":"OG001","value":"145.0","lowerLimit":"39.0","upperLimit":"349.5"}]}]},{"title":"CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"55.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"21.0"}]}]},{"title":"CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"254.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"28.0"}]}]},{"title":"CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"128.5","lowerLimit":"26.0","upperLimit":"281.0"},{"groupId":"OG001","value":"14.0","lowerLimit":"1.0","upperLimit":"48.0"}]}]},{"title":"CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"140.5"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"34.5"}]}]},{"title":"CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"244.0","lowerLimit":"127.0","upperLimit":"356.0"},{"groupId":"OG001","value":"32.0","lowerLimit":"1.0","upperLimit":"77.5"}]}]},{"title":"CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"17.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"6.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"15.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"1.0","upperLimit":"67.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"23.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"28.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"25.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"11.5"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"27.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"6.5"}]}]},{"title":"CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"21.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"41.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"28.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"19.0"}]}]},{"title":"CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"15.5"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32.0","lowerLimit":"1.0","upperLimit":"107.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"31.5"}]}]},{"title":"CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"6.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"19.5"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"13.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.0","lowerLimit":"1.0","upperLimit":"49.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"13.0"}]}]},{"title":"CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"5.0"}]}]},{"title":"CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"15.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"15.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"13.0"}]}]},{"title":"CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"13.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"13.0"}]}]},{"title":"CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"24.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"21.0"}]}]},{"title":"CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"138.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"114.0"}]}]},{"title":"CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"169.0"},{"groupId":"OG001","value":"25.5","lowerLimit":"1.0","upperLimit":"158.0"}]}]},{"title":"CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","lowerLimit":"1.0","upperLimit":"45.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"36.0"}]}]},{"title":"CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"30.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"74.5"}]}]},{"title":"CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","lowerLimit":"1.0","upperLimit":"128.0"},{"groupId":"OG001","value":"11.0","lowerLimit":"1.0","upperLimit":"117.0"}]}]},{"title":"CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74.0","lowerLimit":"1.0","upperLimit":"305.0"},{"groupId":"OG001","value":"61.0","lowerLimit":"1.0","upperLimit":"181.0"}]}]},{"title":"CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"210.0","lowerLimit":"48.0","upperLimit":"620.0"},{"groupId":"OG001","value":"91.5","lowerLimit":"29.0","upperLimit":"329.5"}]}]},{"title":"CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"956.0","lowerLimit":"279.0","upperLimit":"1540.5"},{"groupId":"OG001","value":"159.0","lowerLimit":"62.0","upperLimit":"329.5"}]}]},{"title":"CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"814.5","lowerLimit":"483.0","upperLimit":"1545.5"},{"groupId":"OG001","value":"215.0","lowerLimit":"71.0","upperLimit":"686.5"}]}]},{"title":"CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"543.5","lowerLimit":"286.0","upperLimit":"1057.0"},{"groupId":"OG001","value":"112.0","lowerLimit":"38.5","upperLimit":"257.5"}]}]},{"title":"CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-) at Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","lowerLimit":"1.0","upperLimit":"57.0"},{"groupId":"OG001","value":"21.0","lowerLimit":"1.0","upperLimit":"57.0"}]}]},{"title":"CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89.0","lowerLimit":"14.0","upperLimit":"185.0"},{"groupId":"OG001","value":"26.0","lowerLimit":"1.0","upperLimit":"67.0"}]}]},{"title":"CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"152.0","lowerLimit":"93.0","upperLimit":"256.0"},{"groupId":"OG001","value":"35.0","lowerLimit":"2.0","upperLimit":"98.0"}]}]},{"title":"CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"190.5","lowerLimit":"95.0","upperLimit":"392.0"},{"groupId":"OG001","value":"52.5","lowerLimit":"8.5","upperLimit":"107.0"}]}]},{"title":"CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.0","lowerLimit":"45.0","upperLimit":"181.0"},{"groupId":"OG001","value":"25.5","lowerLimit":"1.0","upperLimit":"88.5"}]}]},{"title":"CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"52.0","lowerLimit":"1.0","upperLimit":"113.0"},{"groupId":"OG001","value":"42.0","lowerLimit":"9.0","upperLimit":"126.0"}]}]},{"title":"CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"180.0","lowerLimit":"71.0","upperLimit":"422.0"},{"groupId":"OG001","value":"81.0","lowerLimit":"28.0","upperLimit":"177.5"}]}]},{"title":"CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41.0","lowerLimit":"1.0","upperLimit":"130.0"},{"groupId":"OG001","value":"14.0","lowerLimit":"1.0","upperLimit":"39.0"}]}]},{"title":"CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"136.0","lowerLimit":"49.0","upperLimit":"242.0"},{"groupId":"OG001","value":"22.5","lowerLimit":"1.0","upperLimit":"89.0"}]}]},{"title":"CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.0","lowerLimit":"1.0","upperLimit":"116.0"},{"groupId":"OG001","value":"7.5","lowerLimit":"1.0","upperLimit":"22.0"}]}]},{"title":"CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.0","lowerLimit":"1.0","upperLimit":"184.0"},{"groupId":"OG001","value":"42.0","lowerLimit":"1.0","upperLimit":"188.0"}]}]},{"title":"CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"242.0","lowerLimit":"51.0","upperLimit":"430.0"},{"groupId":"OG001","value":"72.0","lowerLimit":"1.0","upperLimit":"186.0"}]}]},{"title":"CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","lowerLimit":"39.5","upperLimit":"159.5"},{"groupId":"OG001","value":"9.0","lowerLimit":"1.0","upperLimit":"47.0"}]}]},{"title":"CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"136.5","lowerLimit":"58.0","upperLimit":"266.5"},{"groupId":"OG001","value":"16.5","lowerLimit":"1.0","upperLimit":"78.5"}]}]},{"title":"CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"51.5","lowerLimit":"5.0","upperLimit":"127.0"},{"groupId":"OG001","value":"6.0","lowerLimit":"1.0","upperLimit":"48.5"}]}]},{"title":"CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42.0","lowerLimit":"1.0","upperLimit":"124.0"},{"groupId":"OG001","value":"21.0","lowerLimit":"1.0","upperLimit":"77.0"}]}]},{"title":"CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"186.0","lowerLimit":"14.0","upperLimit":"334.0"},{"groupId":"OG001","value":"20.5","lowerLimit":"1.0","upperLimit":"118.5"}]}]},{"title":"CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"121.0","lowerLimit":"28.5","upperLimit":"325.5"},{"groupId":"OG001","value":"28.0","lowerLimit":"1.0","upperLimit":"101.0"}]}]},{"title":"CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"118.0","lowerLimit":"19.0","upperLimit":"335.5"},{"groupId":"OG001","value":"44.0","lowerLimit":"1.0","upperLimit":"186.0"}]}]},{"title":"CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94.0","lowerLimit":"20.0","upperLimit":"267.0"},{"groupId":"OG001","value":"29.0","lowerLimit":"1.0","upperLimit":"97.0"}]}]},{"title":"CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"71.0"},{"groupId":"OG001","value":"26.0","lowerLimit":"1.0","upperLimit":"99.0"}]}]},{"title":"CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.0","lowerLimit":"1.0","upperLimit":"195.0"},{"groupId":"OG001","value":"16.5","lowerLimit":"1.0","upperLimit":"66.5"}]}]},{"title":"CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92.5","lowerLimit":"1.0","upperLimit":"184.5"},{"groupId":"OG001","value":"59.0","lowerLimit":"1.0","upperLimit":"196.0"}]}]},{"title":"CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","lowerLimit":"1.0","upperLimit":"124.5"},{"groupId":"OG001","value":"8.5","lowerLimit":"1.0","upperLimit":"152.0"}]}]},{"title":"CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32.0","lowerLimit":"1.0","upperLimit":"190.0"},{"groupId":"OG001","value":"21.0","lowerLimit":"1.0","upperLimit":"156.0"}]}]},{"title":"CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71.0","lowerLimit":"9.0","upperLimit":"231.0"},{"groupId":"OG001","value":"51.0","lowerLimit":"1.0","upperLimit":"128.0"}]}]},{"title":"CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"708.0","lowerLimit":"158.0","upperLimit":"1621.0"},{"groupId":"OG001","value":"86.5","lowerLimit":"5.0","upperLimit":"381.0"}]}]},{"title":"CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","lowerLimit":"7.5","upperLimit":"110.0"},{"groupId":"OG001","value":"22.0","lowerLimit":"1.0","upperLimit":"85.0"}]}]},{"title":"CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83.0","lowerLimit":"2.5","upperLimit":"206.0"},{"groupId":"OG001","value":"15.5","lowerLimit":"1.0","upperLimit":"82.0"}]}]},{"title":"CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","lowerLimit":"1.0","upperLimit":"152.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"45.0"}]}]}]},{"type":"SECONDARY","title":"Desciptive Statistics of the Frequency of M72-specific CD8+ T-cells Expressing Any Combination of Immune Markers in the Safety and Immune Sub-cohort","description":"The frequency of M72-specific CD8 + T-cells per million cells were identified after in vitro stimulation expressing any combination of immune markers ( Interleukin-2 (IL-2), cluster of differentiation 40-ligand (CD40-L), tumor necrosis factor alpha (TNF-) and interferon-gamma (IFN-) after background subtraction for each treatment group.","populationDescription":"Analysis was performed on the \"safety and immunogenicity\" sub-cohort (i.e. about 150 subjects enrolled in each group and from 2 of the 3 countries \\[the third country study start was delayed as awaiting regulatory approval\\]) which included subjects with at least 1 immune result documented.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"T cells per million cells","timeFrame":"Prior to dose 1 (Day 0) and post-dose 2 (Day 60, Year 1, Year 2 and Year 3)","groups":[{"id":"OG000","title":"M72AS01 Group","description":"Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."},{"id":"OG001","title":"Control Group","description":"Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"74"}]}],"classes":[{"title":"CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"74"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.5","lowerLimit":"1.0","upperLimit":"101.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"25.0"}]}]},{"title":"CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"74"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"34.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"74"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"74"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"74"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"74"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"74"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"20.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"187.5"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"95.0"}]}]},{"title":"CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"112.0"},{"groupId":"OG001","value":"9.5","lowerLimit":"1.0","upperLimit":"64.0"}]}]},{"title":"CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"65.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"41.0"}]}]},{"title":"CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"74"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"96.0"},{"groupId":"OG001","value":"4.0","lowerLimit":"1.0","upperLimit":"79.0"}]}]},{"title":"CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","lowerLimit":"1.0","upperLimit":"110.0"},{"groupId":"OG001","value":"12.0","lowerLimit":"1.0","upperLimit":"89.0"}]}]},{"title":"CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"43.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"74"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"45.0","lowerLimit":"1.0","upperLimit":"96.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"37.0"}]}]},{"title":"CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42.0","lowerLimit":"1.0","upperLimit":"75.0"},{"groupId":"OG001","value":"24.0","lowerLimit":"1.0","upperLimit":"51.0"}]}]},{"title":"CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"74"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"27.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"27.0"}]}]},{"title":"CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"14.0"}]}]},{"title":"CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"74"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"154.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"235.0"}]}]},{"title":"CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.0","lowerLimit":"1.0","upperLimit":"225.0"},{"groupId":"OG001","value":"15.5","lowerLimit":"1.0","upperLimit":"155.0"}]}]},{"title":"CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"59.5"},{"groupId":"OG001","value":"24.0","lowerLimit":"1.0","upperLimit":"73.0"}]}]},{"title":"CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"74"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","lowerLimit":"1.0","upperLimit":"104.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"64.0"}]}]},{"title":"CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"63.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"72.0"}]}]},{"title":"CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"56.5"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"81.0"}]}]},{"title":"CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"74"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"33.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"44.0"}]}]},{"title":"CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"66.0"},{"groupId":"OG001","value":"6.0","lowerLimit":"1.0","upperLimit":"131.0"}]}]},{"title":"CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"22.5"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"65.0"}]}]},{"title":"CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.0","lowerLimit":"1.0","upperLimit":"64.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"2.0"}]}]},{"title":"CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"137.5"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"79.0"}]}]},{"title":"CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"74"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"156.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"125.0"}]}]},{"title":"CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"104.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"313.0"}]}]},{"title":"CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+) at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"54"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.0","lowerLimit":"1.0","upperLimit":"750"},{"groupId":"OG001","value":"13.5","lowerLimit":"1.0","upperLimit":"2701"}]}]},{"title":"CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+) at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","lowerLimit":"1.0","upperLimit":"477"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1033"}]}]},{"title":"CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+) at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"1.0","upperLimit":"2981"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"2819"}]}]},{"title":"CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+) at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"74"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"978"},{"groupId":"OG001","value":"3.0","lowerLimit":"1.0","upperLimit":"777"}]}]},{"title":"CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+) at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"1.0","upperLimit":"1384"},{"groupId":"OG001","value":"16.0","lowerLimit":"1.0","upperLimit":"537"}]}]}]},{"type":"SECONDARY","title":"M72-specific Antibody Concentrations as Measured by Enzyme Linked Immuno Sorbent Assay (ELISA) in the Safety and Immune Sub-cohort","description":"Mycobacterium tuberculosis M72-specific antibody geometric mean concentrations (GMCs) with exact 95% Confidence Interval (CI) were measured by Enzyme Linked Immuno Sorbent Assay (ELISA) and expressed in ELISA unit per milliliter (EU/mL). The cut-off of the assay was 2.8 EU/mL. The Geometric Mean Concentration (GMC) calculations were performed by taking the anti-log of the mean of the log10 concentration transformations. For descriptive statistics purposes only, antibody concentrations below the cut-off value of the assay was given an arbitrary value of half the cut-off value for the purpose of GMC calculation.","populationDescription":"Analysis was performed on the \"safety and immunogenicity\" sub-cohort (i.e. about 150 subjects enrolled in each group and from 2 of the 3 countries \\[the third country study start was delayed as awaiting regulatory approval\\]) which included subjects with at least 1 cell-mediated immune result documented.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EU/mL","timeFrame":"Prior to dose 1 (Day 0) and post-dose 2 (Day 60, Year 1, Year 2 and Year 3)","groups":[{"id":"OG000","title":"M72AS01 Group","description":"Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."},{"id":"OG001","title":"Control Group","description":"Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"124"}]}],"classes":[{"title":"Anti-M72 at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"124"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"1.5","upperLimit":"1.8"},{"groupId":"OG001","value":"1.6","lowerLimit":"1.5","upperLimit":"1.7"}]}]},{"title":"Anti-M72 at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"97"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"547.0","lowerLimit":"471.1","upperLimit":"635.1"},{"groupId":"OG001","value":"1.6","lowerLimit":"1.4","upperLimit":"1.7"}]}]},{"title":"Anti-M72 at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"119"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41.5","lowerLimit":"35.4","upperLimit":"48.6"},{"groupId":"OG001","value":"1.7","lowerLimit":"1.5","upperLimit":"1.8"}]}]},{"title":"Anti-M72 at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","lowerLimit":"26.2","upperLimit":"35.6"},{"groupId":"OG001","value":"1.6","lowerLimit":"1.5","upperLimit":"1.8"}]}]},{"title":"Anti-M72 at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"92"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27.0","lowerLimit":"22.7","upperLimit":"32.0"},{"groupId":"OG001","value":"1.6","lowerLimit":"1.4","upperLimit":"1.7"}]}]}]},{"type":"SECONDARY","title":"Number of Seropositive Subjects for M72 Antibodies Measured by ELISA in the Safety and Immune Sub-cohort","description":"A seronegative subject was a subject whose antibody concentration was below 2.8 EU/mL, while a seropositive subject was a subject whose antibody concentration was greater than or equal to 2.8 EU/mL.","populationDescription":"Analysis was performed on the \"safety and immunogenicity\" sub-cohort (i.e. about 150 subjects enrolled in each group and from 2 of the 3 countries \\[the third country study start was delayed as awaiting regulatory approval\\]) which included subjects with at least 1 cell-mediated immune result documented.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Prior to dose 1 (Day 0) and post-dose 2 (Day 60, Year 1, Year 2 and Year 3)","groups":[{"id":"OG000","title":"M72AS01 Group","description":"Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."},{"id":"OG001","title":"Control Group","description":"Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"124"}]}],"classes":[{"title":"Anti-M72 at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"124"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"12"}]}]},{"title":"Anti-M72 at Day 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"97"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"8"}]}]},{"title":"Anti-M72 at Year 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"119"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"14"}]}]},{"title":"Anti-M72 at Year 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"11"}]}]},{"title":"Anti-M72 at Year 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"92"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"8"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Solicited local and general symptoms were reported during the 7-day (Days 0-6) post-vaccination period and unsolicited AE(s): during the 30-day (Days 0-29) post-vaccination period. SAE(s): were reported during the entire study period (from Month 0 to Month 36 (Year 3).","eventGroups":[{"id":"EG000","title":"M72AS01 Group","description":"Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm.","deathsNumAffected":19,"deathsNumAtRisk":1786,"seriousNumAffected":51,"seriousNumAtRisk":1786,"otherNumAffected":1204,"otherNumAtRisk":1786},{"id":"EG001","title":"Control Group","description":"Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm.","deathsNumAffected":28,"deathsNumAtRisk":1787,"seriousNumAffected":62,"seriousNumAtRisk":1787,"otherNumAffected":809,"otherNumAtRisk":1787}],"seriousEvents":[{"term":"Hypochromic anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Iron deficiency anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Cardiac disorder","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Ventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Basedow's disease","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Faecaloma","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Haematemesis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Large intestine perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Accidental death","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Hepatic cirrhosis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Abscess limb","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Acute hiv infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Lymph node tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Malaria","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Pelvic inflammatory disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Subcutaneous abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Tuberculosis gastrointestinal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Typhoid fever","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Chest injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Crush injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Foot fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Gun shot wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1786},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":1787}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Limb injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Lumbar vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Multiple injuries","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Pneumothorax traumatic","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Poisoning","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Post-traumatic neck syndrome","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Soft tissue injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Splenic rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Stab wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Thermal burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Traumatic haemothorax","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Wound haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Cervix carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Squamous cell carcinoma of lung","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Haemorrhage intracranial","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Hepatic encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Hypertensive encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Abortion incomplete","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Ectopic pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Foetal distress syndrome","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Pre-eclampsia","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Premature baby","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Premature separation of placenta","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Prolonged labour","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Ruptured ectopic pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Schizophrenia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Substance abuse","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Substance-induced psychotic disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Dysfunctional uterine bleeding","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Uterine polyp","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Erythema nodosum","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Eosinophilia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Hypochromic anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Immune thrombocytopenic purpura","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Iron deficiency anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Lymph node calcification","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Lymph node pain","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Lymphadenitis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Splenomegaly","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Cerumen impaction","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Ear disorder","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Ear pain","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1786},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":1787}]},{"term":"Ear pruritus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Hypoacusis","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Motion sickness","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Goitre","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Conjunctival haemorrhage","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Conjunctivitis allergic","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":1787}]},{"term":"Eye discharge","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Eye pain","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":1786},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":1787}]},{"term":"Eye pruritus","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":1787}]},{"term":"Eye swelling","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Eyelid cyst","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Ocular hyperaemia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Visual impairment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":1786},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":1787}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":64,"numAffected":59,"numAtRisk":1786},{"groupId":"EG001","numEvents":61,"numAffected":48,"numAtRisk":1787}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":23,"numAtRisk":1786},{"groupId":"EG001","numEvents":30,"numAffected":28,"numAtRisk":1787}]},{"term":"Anal fissure","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Anal pruritus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Anal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Anorectal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Cheilitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Dental caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":50,"numAffected":45,"numAtRisk":1786},{"groupId":"EG001","numEvents":37,"numAffected":30,"numAtRisk":1787}]},{"term":"Diarrhoea haemorrhagic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":1787}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Food poisoning","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Gastric disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":1786},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":1787}]},{"term":"Gastrointestinal sounds abnormal","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Gingival bleeding","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Gingival pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":1787}]},{"term":"Lip blister","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Lip swelling","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Mouth ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":52,"numAffected":47,"numAtRisk":1786},{"groupId":"EG001","numEvents":26,"numAffected":25,"numAtRisk":1787}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Oral contusion","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Oral pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Peptic ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Proctalgia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Rectal prolapse","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Tooth impacted","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":16,"numAtRisk":1786},{"groupId":"EG001","numEvents":25,"numAffected":22,"numAtRisk":1787}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":34,"numAtRisk":1786},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":1787}]},{"term":"Administration site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":19,"numAtRisk":1786},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":1787}]},{"term":"Axillary pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":30,"numAtRisk":1786},{"groupId":"EG001","numEvents":22,"numAffected":19,"numAtRisk":1787}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":78,"numAffected":72,"numAtRisk":1786},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":1787}]},{"term":"Facial pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":134,"numAffected":115,"numAtRisk":1786},{"groupId":"EG001","numEvents":58,"numAffected":51,"numAtRisk":1787}]},{"term":"Feeling cold","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":1786},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":1787}]},{"term":"Feeling hot","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":33,"numAtRisk":1786},{"groupId":"EG001","numEvents":20,"numAffected":17,"numAtRisk":1787}]},{"term":"Feeling of body temperature change","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Hangover","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Hypothermia","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Ill-defined disorder","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":1786},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":1787}]},{"term":"Injection site bruising","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Injection site discolouration","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":66,"numAffected":65,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Injection site hypersensitivity","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Injection site hypoaesthesia","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Injection site induration","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Injection site joint pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Injection site lymphadenopathy","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Injection site movement impairment","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":848,"numAffected":616,"numAtRisk":1786},{"groupId":"EG001","numEvents":87,"numAffected":75,"numAtRisk":1787}]},{"term":"Injection site papule","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Injection site pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":27,"numAtRisk":1786},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":1787}]},{"term":"Injection site rash","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Injection site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":221,"numAffected":192,"numAtRisk":1786},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":1787}]},{"term":"Injection site vesicles","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Injection site warmth","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Injury associated with device","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":35,"numAtRisk":1786},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":1787}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":74,"numAffected":63,"numAtRisk":1786},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":1787}]},{"term":"Peripheral swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":142,"numAffected":121,"numAtRisk":1786},{"groupId":"EG001","numEvents":22,"numAffected":22,"numAtRisk":1787}]},{"term":"Suprapubic pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Thirst","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Vaccination site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Vessel puncture site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":1787}]},{"term":"Vessel puncture site pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Hepatomegaly","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Hyperbilirubinaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Food allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Abscess jaw","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Abscess limb","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Acarodermatitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Amoebiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Anal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Anorectal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Ascariasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Atypical mycobacterial infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Bacterial vaginosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Body tinea","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Breast abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":1787}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Candida infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Carbuncle","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Cervicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":1786},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":1787}]},{"term":"Conjunctivitis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Dysentery","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Ear infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Folliculitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":1787}]},{"term":"Fungal skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Furuncle","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":1786},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":1787}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Gingival abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Gingivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Groin abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Helicobacter infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Helminthic infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Herpes simplex","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Hiv infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Impetigo","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Infected bite","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":67,"numAffected":62,"numAtRisk":1786},{"groupId":"EG001","numEvents":54,"numAffected":51,"numAtRisk":1787}]},{"term":"Injection site abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Injection site pustule","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Laryngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":1786},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":1787}]},{"term":"Malaria","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":53,"numAffected":52,"numAtRisk":1786},{"groupId":"EG001","numEvents":57,"numAffected":54,"numAtRisk":1787}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":1786},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":1787}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Oral herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":1787}]},{"term":"Orchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Otitis media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":1787}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Pelvic inflammatory disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Periodontitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":1786},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":1787}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":1787}]},{"term":"Rash pustular","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1786},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":1787}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":22,"numAtRisk":1786},{"groupId":"EG001","numEvents":29,"numAffected":29,"numAtRisk":1787}]},{"term":"Salmonellosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Sexually transmitted disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":1786},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":1787}]},{"term":"Skin bacterial infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Subcutaneous abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":1787}]},{"term":"Tinea capitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Tinea infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Tinea pedis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Tinea versicolour","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":1786},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":1787}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1786},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":1787}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Typhoid fever","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":70,"numAffected":64,"numAtRisk":1786},{"groupId":"EG001","numEvents":76,"numAffected":72,"numAtRisk":1787}]},{"term":"Urethritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":1786},{"groupId":"EG001","numEvents":16,"numAffected":15,"numAtRisk":1787}]},{"term":"Vaginal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Varicella","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Viral rash","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Vulval abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Vulvovaginal candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Vulvovaginal mycotic infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":1787}]},{"term":"Wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Alcohol poisoning","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Animal bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Arthropod bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Arthropod sting","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Eye contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Face injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Gun shot wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Hand fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Heat stroke","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Injection related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":1787}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Limb injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":1787}]},{"term":"Lip injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Mouth injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Muscle strain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Penis injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Radius fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Scar","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Skin abrasion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Skin injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1786},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":1787}]},{"term":"Soft tissue injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Stab wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Tendon injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Thermal burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Upper limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Vaccination complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":1787}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1786},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":1787}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1786},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":1787}]},{"term":"Blood pressure diastolic increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":1786},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":1787}]},{"term":"Blood pressure systolic increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Body temperature decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":1787}]},{"term":"Body temperature increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Haematocrit decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Heart rate increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Hiv test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":1786},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":1787}]},{"term":"Neutrophil count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Respiratory rate increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":1786},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":1787}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"White blood cell count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":33,"numAtRisk":1786},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":1787}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Gout","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Hypoalbuminanemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Increased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":31,"numAtRisk":1786},{"groupId":"EG001","numEvents":22,"numAffected":21,"numAtRisk":1787}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Arthropathy","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":76,"numAffected":66,"numAtRisk":1786},{"groupId":"EG001","numEvents":35,"numAffected":32,"numAtRisk":1787}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Bone swelling","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Joint stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Joint swelling","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Limb discomfort","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":1787}]},{"term":"Mobility decreased","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":1787}]},{"term":"Muscle twitching","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1786},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":1787}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":1786},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":1787}]},{"term":"Musculoskeletal stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":88,"numAffected":84,"numAtRisk":1786},{"groupId":"EG001","numEvents":28,"numAffected":25,"numAtRisk":1787}]},{"term":"Myositis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":15,"numAtRisk":1786},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":1787}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":26,"numAtRisk":1786},{"groupId":"EG001","numEvents":18,"numAffected":18,"numAtRisk":1787}]},{"term":"Pain in jaw","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Rotator cuff syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Anogenital warts","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Fibroadenoma of breast","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Skin papilloma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Ageusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":132,"numAffected":120,"numAtRisk":1786},{"groupId":"EG001","numEvents":104,"numAffected":93,"numAtRisk":1787}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":879,"numAffected":620,"numAtRisk":1786},{"groupId":"EG001","numEvents":483,"numAffected":341,"numAtRisk":1787}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":1786},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":1787}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Neuritis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Optic neuritis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Poor quality sleep","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Post-traumatic headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Tension headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":1787}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":1787}]},{"term":"Libido increased","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Hypertonic bladder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Micturition disorder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Urethral discharge","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Breast mass","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Breast pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Dysfunctional uterine bleeding","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Dysmenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":1786},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":1787}]},{"term":"Erectile dysfunction","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Genital ulceration","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Menorrhagia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1786},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":1787}]},{"term":"Menstruation irregular","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Metrorrhagia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Pelvic pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Penile discharge","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Pruritus genital","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Scrotal pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Vaginal discharge","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Vaginal haemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Bronchial hyperreactivity","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Bronchospasm","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":32,"numAtRisk":1786},{"groupId":"EG001","numEvents":39,"numAffected":38,"numAtRisk":1787}]},{"term":"Dry throat","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Lower respiratory tract congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":1787}]},{"term":"Nocturnal dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1786},{"groupId":"EG001","numEvents":16,"numAffected":15,"numAtRisk":1787}]},{"term":"Painful respiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Pharyngeal oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Pleuritic pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Respiratory symptom","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Respiratory tract congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Rhinalgia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Rhinitis allergic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":1787}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":1786},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":1787}]},{"term":"Sneezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":1787}]},{"term":"Throat irritation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Acne","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":1787}]},{"term":"Blister","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Dermatitis allergic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":1787}]},{"term":"Dermatitis contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Dermatosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":1787}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Erythema multiforme","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":1786},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":1787}]},{"term":"Hyperkeratosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Miliaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Night sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Penile ulceration","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1786},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":1787}]},{"term":"Pruritus generalised","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":1786},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":1787}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":16,"numAtRisk":1786},{"groupId":"EG001","numEvents":18,"numAffected":18,"numAtRisk":1787}]},{"term":"Rash generalised","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Rash morbilliform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Rash papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Rash pruritic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":1786},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1787}]},{"term":"Seborrhoeic dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Skin exfoliation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Skin lesion","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Swelling face","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Trichorrhexis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1786},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1787}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Bloody discharge","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Hot flush","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":1786},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":1787}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Phlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1787}]},{"term":"Systolic hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Varicose vein","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]},{"term":"Vascular pain","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1786},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1787}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"GSK Response Center","organization":"GlaxoSmithKline","email":"GSKClinicalSupportHD@gsk.com","phone":"866-435-7343"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2014-01-29","uploadDate":"2019-11-12T09:28","filename":"Prot_000.pdf","size":2297612},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2017-10-17","uploadDate":"2019-11-12T09:28","filename":"SAP_001.pdf","size":562980}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D014376","term":"Tuberculosis"}],"ancestors":[{"id":"D009164","term":"Mycobacterium Infections"},{"id":"D000193","term":"Actinomycetales Infections"},{"id":"D016908","term":"Gram-Positive Bacterial Infections"},{"id":"D001424","term":"Bacterial Infections"},{"id":"D001423","term":"Bacterial Infections and Mycoses"},{"id":"D007239","term":"Infections"}]}},"hasResults":true}